US FDA OK's use of antihistamine Xyzal in younger children
This article was originally published in Scrip
Executive Summary
The US FDA has granted UCB and Sanofi-Aventis's antihistamine Xyzal (levocetirizine dihydrochloride), in tablet and liquid formulations, a wider label to include infants and young children. Since its 2007 approval, Xyzal has only been used in children aged six and older.